Saaristo A, Karpanen T, Alitalo K
Molecular/Cancer Biology Laboratory and Ludwig Institute for Cancer Research, University of Helsinki, Finland.
Oncogene. 2000 Dec 11;19(53):6122-9. doi: 10.1038/sj.onc.1203969.
There is a constant requirement for vascular supply in solid tumors. Tumor-associated neovascularization allows the tumor cells to express their critical growth advantage. Axillary lymph node status is the most important prognostic factor in operable breast cancer, and experimental and clinical evidence suggests that the process of metastasis is also angiogenesis-dependent. Various angiogenic growth factors and cytokines induce neovascularization in tumors, namely members of the vascular endothelial growth factor (VEGF) and angiopoietin (Ang) gene families. A strong correlation has been found between VEGF expression and increased tumor microvasculature, malignancy, and metastasis in breast cancer. Anti-angiogenic therapy approaches offer a new promising anti-cancer strategy and a remarkably diverse group of over 20 such drugs is currently undergoing evaluation in clinical trials.
实体瘤对血管供应有持续需求。肿瘤相关的新血管生成使肿瘤细胞能够发挥其关键的生长优势。腋窝淋巴结状态是可手术乳腺癌最重要的预后因素,实验和临床证据表明转移过程也依赖于血管生成。多种血管生成生长因子和细胞因子可诱导肿瘤中的新血管生成,即血管内皮生长因子(VEGF)和血管生成素(Ang)基因家族的成员。已发现VEGF表达与乳腺癌中肿瘤微血管增加、恶性程度和转移之间存在密切相关性。抗血管生成治疗方法提供了一种新的有前景的抗癌策略,目前有超过20种这类药物正在进行临床试验评估。